[WEBINAR] So Much to Lose: Changing landscape of obesity in America

Would you take a medication that would help you lose weight? That’s the question many Americans have been considering since a class of drugs known as GLP-1s (newer brands include Mounjaro, Ozempic, and Wegovy) became popularized by celebrities and influencers earlier this year.

According to the latest Ipsos Consumer Tracker, over half (54%) of Americans are interested in medication to help them lose weight. With two new GLP-1s now FDA approved for weight loss, there are broader implications for sectors from healthcare to food & beverage to airlines if America can find ways to treat its epidemics of obesity.

Join our Ipsos experts as we dive into the implications of new obesity treatments, including:

  • What Americans believe about obesity, and how that differs by demographics
  • What Americans are discussing about obesity and obesity treatments
  • Equity considerations regarding access to these treatments
  • Implications for a broad set of industries

Access Recording

Registering will also ensure you receive a direct link to the recording once published, and notification of future events or Ipsos thought leadership on this topic.

Speakers :

  • Scott Morano, SVP, Ipsos Healthcare

  • Chareen Lim, SVP Ipsos Healthcare

  • Steve Girling, President Ipsos Healthcare

Consumer & Shopper